Tag Archives: bmy

Bristol Defends Data; Roche Shines In Cancer Showdown

Bristol-Myers Squibb (BMY) reported stellar results for a clinical trial in advanced melanoma Monday, but its stock was down more than 1% in afternoon trading on the stock market today as Wall Street digested a weekend filled with cancer news. At the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, Bristol reported that the two-year survival rate of patients taking immuno-oncology (I-O) drugs nivolumab with Yervoy was 88%.

Bristol-Myers Downgraded On Lung-Cancer Drug Data

Bristol-Myers Squibb (BMY) was down more than 6% on the stock market today after the company’s latest cancer-drug data moved one analyst to downgrade the stock, though others saw little that was unexpected. Late Wednesday, the abstracts for various presentations at the upcoming American Society for Clinical Oncology (ASCO) meeting went online, including phase-two data on Bristol’s much-anticipated immuno-oncology candidate nivolumab in combination

Bristol, Merck, Sanofi Report Soft Q1 Sales

Three big pharmas reported light-to-mixed Q1 earnings Tuesday, but their shares went in different directions in the stock market today as Wall Street seemed to focus on different details of the reports. Bristol-Myers Squibb (BMY) said Q1 earnings rose 12% over the year-earlier quarter to 46 cents a share, beating analysts’ consensus by 3 cents. Sales, however, fell 1% to $3.8 billion, missing consensus of $3.9 billion. Bristol added a nickel to